Last updated: 11/04/2018 06:30:19
Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer
EudraCT ID
EU CT Number
Not applicable
Trial status
Other
Other
Trial overview
Official title: An open-label, multi-centre study of lapatinib in combinationwith chemotherapy in patients with ErbB2 overexpressing breastcancer after trastuzumab failure in the neoadjuvant or adjuvantsetting.
Trial description: This study will evaluate the safety and efficacy of lapatinib in combination with chemotherapy (capecitabine, docetaxel, nab-paclitaxel) in subjects with ErbB2-overexpressing breast cancer whose disease has progressed during or within 12 months after completion of trastuzumab-containing therapy in the neoadjuvant or adjuvant setting.
Primary purpose:
Treatment
Trial design:
Single Group Assignment
Masking:
None (Open Label)
Allocation:
Not applicable
Primary outcomes:
Overall Tumor Response
Timeframe: from start of treatment and every 6 weeks (wks) until Wk 12, then every 12 wks thereafter through the end of treatment (~95 wks; dependent on when participant discontinued study therapy due to disease progression, death, adverse event, of other reason)
Secondary outcomes:
Clinical Benefit (CB)
Timeframe: from start of treatment and every 6 weeks (wks) until Wk 12, then every 12 wks thereafter through the end of treatment (~95 weeks; dependent on when participant discontinued study therapy due to disease progression, death, adverse event, or other reason)
Duration of response
Timeframe: time from first documented evidence of CR or PR until the first documented sign of disease progression or death (approximately 95 weeks)
Time to Response (TTR)
Timeframe: start of treatment until first documented evidence of CR or PR (approximately 95 weeks)
Progression-free survival
Timeframe: from start of treatment and every 6 weeks (wks) until Wk 12, then every 12 wks thereafter through the end of treatment (~95 weeks); dependent on when participant discontinued study therapy due to disease progression, death, adverse event, or other reason)
Number of participants with the indicated serious adverse events and adverse events
Timeframe: Baseline through End of Treatment, or discontinuation of study therapy (approximately 95 weeks); from the first dose of lapatinib until 5 days after the last dose of lapatinib
Interventions:
Enrollment:
9
Primary completion date:
2009-01-09
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Not applicable
Medical condition
Relapsed Breast Cancer
Product
lapatinib
Collaborators
Not applicable
Study date(s)
November 2007 to September 2009
Type
Interventional
Phase
2
Participation criteria
Sex
Female
Age
18+ years
Accepts healthy volunteers
No
- Signed informed consent.
- Pregnant or lactating females.
- Women of childbearing potential who do not practice approved contraceptive methods (for example, intrauterine device [IUD], birth control pills, or barrier device) beginning 2 weeks before the first dose of investigational product and for 28 days after the final dose of investigational product.
Inclusion and exclusion criteria
Inclusion criteria:
- Signed informed consent.
- Histologically/cytologically confirmed breast cancer; If the disease is restricted to a solitary lesion, the neoplastic nature of the lesion must be confirmed by cytology or histology.
- Measurable lesion(s) according to RECIST (Response Evaluation Criteria in Solid Tumors) [Therasse, 2000].
- Documented amplification of the ErbB2 gene by fluorescence in situ hybridization (FISH) or documented overexpression of the ErbB2 protein by 3+ IHC in primary or metastatic tumor tissue.
- Subjects must have relapsed breast cancer where the disease progressed during or ≤ 12 months after completion of trastuzumab-containing therapy in the neoadjuvant or adjuvant setting. Note: Progression is defined using RECIST criteria, that is, either the appearance of new lesions or a >=20% increase in the sum of longest diameter (LD).
- Subjects must not have received prior anti-cancer therapy for metastatic breast cancer (MBC). Subjects who received prior antihormonal agents combined with trastuzumab for the treatment of disease which first presented as ER positive MBC and recurred while receiving trastuzumab or ≤ 3 months after completing this therapy are eligible.
- Subjects with stable central nervous system (CNS) metastases as confirmed by computerized tomography (CT)/magnetic resonance imaging (MRI) are allowed. Treatment with prophylactic anticonvulsants is permitted, unless listed within the Prohibited Medications.
- Subjects must have a baseline cardiac ejection fraction (LVEF) ³50% measured by echocardiogram (ECHO) (or multigated acquisition (MUGA) scan if an ECHO cannot be performed). The same modality used at baseline must be used for repeat assessment throughout study. Only subjects with controlled or asymptomatic angina or arrhythmias are eligible.
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0
- 2.
- Subjects must have archived tumor tissue from the initial diagnosis available for analysis. If tissue from the initial diagnosis is not available, then tissue must be obtained from a recurrent or metastatic site prior to initiating study treatment.
- Female ≥18 years.
- Subject must have adequate organ function as defined in Table 1.
- Table 1: Baseline Laboratory Values for Adequate Organ Function. SYSTEM Hematologic: Absolute neutrophil count: ≥1.5 X 10^9/L Hemoglobin: ≥9 g/dL Platelets: ≥ 75 X 10^9/L Hepatic: AST, ALT and Alkaline phosphatase: ≤ 2.5 X ULN Unless concomitant docetaxel, then ≤ 1.5 x ULN for AST and ALT, with AP ≤ 2.5 x ULN Unless documented liver metastasis, then ≤ 5 x ULN Serum bilirubin: ≤ 2.0 X ULN Albumin: ≥ 2.5 g/dL Renal: Serum Creatinine: ≤ 1.5 mg/dL
- OR
- Calculate Creatinine Clearance: ≥ 40 mL/min 1Calculated by the Cockcroft and Gault Method [Cockcroft , 1976].
Exclusion criteria:
- Pregnant or lactating females.
- Women of childbearing potential who do not practice approved contraceptive methods (for example, intrauterine device [IUD], birth control pills, or barrier device) beginning 2 weeks before the first dose of investigational product and for 28 days after the final dose of investigational product.
- History of other malignancy. However, subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible.
- Concurrent therapy given to treat cancer (chemotherapy, radiation therapy, immunotherapy, biologic therapy, anti-hormonal therapy) while taking study medication.
- Unresolved or unstable, serious toxicity from prior administration of another investigational drug and/or of prior cancer treatment.
- Malabsorption syndrome or resection of the stomach or small bowel significantly affecting gastrointestinal function.
- Have current active haptic or biliary disease (with excpetion of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment).
- Concurrent disease or condition that, in the opinion of the physician, would make the subject inappropriate for study participation or any serious medical disorder that would interfere with the subject's safety (for example, uncontrolled infection, or any psychiatric condition prohibiting understanding or rendering of informed consent).
- Concurrent treatment with an investigational agent or participation in another clinical trial involving investigational agents for anti-cancer therapy.
- Bisphosphonates may not be initiated after the first dose of study medication.
- Considered by the Investigator to have a life expectancy less than 3 months.
- Not able to swallow or retain oral medication.
- The subject with a known unmanageable hypersensitivity reaction or idiosyncrasy to drugs chemically related to lapatinib or excipients and those related to capecitabine, docetaxel, nab paclitaxel or their excipients.
Trial location(s)
Location
GSK Investigational Site
Albuquerque, New Mexico, United States, 87131-0001
Status
Study Complete
Location
GSK Investigational Site
Anaheim, California, United States, 92801
Status
Study Complete
Location
GSK Investigational Site
Voorhees, New Jersey, United States, 08043
Status
Study Complete
Location
GSK Investigational Site
San Antonio, Texas, United States, 78229
Status
Study Complete
Location
GSK Investigational Site
Fairfax, Virginia, United States, 22031
Status
Study Complete
Location
GSK Investigational Site
Hot Springs, Arkansas, United States, 71913
Status
Study Complete
Showing 1 - 6 of 28 Results
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Other
Actual primary completion date
2009-01-09
Actual study completion date
2009-01-09
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website